Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP

IF 15.8 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Resistance Updates Pub Date : 2024-02-17 DOI:10.1016/j.drup.2024.101069

Carole Seguin-Devaux , Tomislav Mestrovic , Jacobus J. Arts , Didem Sen Karaman , Cristina Nativi , Dana Reichmann , Priyanka Sahariah , Younes Smani , Patricia Rijo , Mattia Mori , on behalf of the COST Action CA21145 EURESTOP

引用次数: 0

查看原文本刊更多论文

解决欧洲抗菌药耐药性问题：COST 行动 CA21145 EURESTOP 的多管齐下方法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Resistance Updates 医学-药学

CiteScore

26.20

自引率

11.90%

发文量

审稿时长

29 days

期刊介绍： Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research